Fmr LLC Acquires 931 Shares of NeoGenomics, Inc. (NASDAQ:NEO)

Fmr LLC increased its holdings in NeoGenomics, Inc. (NASDAQ:NEO) by 7.6% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 13,255 shares of the medical research company’s stock after purchasing an additional 931 shares during the period. Fmr LLC’s holdings in NeoGenomics were worth $196,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in NEO. Blue Trust Inc. raised its holdings in shares of NeoGenomics by 107.2% in the 2nd quarter. Blue Trust Inc. now owns 2,331 shares of the medical research company’s stock worth $32,000 after buying an additional 1,206 shares in the last quarter. Canada Pension Plan Investment Board bought a new stake in NeoGenomics in the second quarter valued at $57,000. KBC Group NV raised its stake in NeoGenomics by 33.1% during the third quarter. KBC Group NV now owns 4,530 shares of the medical research company’s stock worth $67,000 after acquiring an additional 1,127 shares in the last quarter. Banque Cantonale Vaudoise lifted its holdings in shares of NeoGenomics by 10.2% during the second quarter. Banque Cantonale Vaudoise now owns 17,575 shares of the medical research company’s stock valued at $244,000 after acquiring an additional 1,633 shares during the period. Finally, SG Americas Securities LLC acquired a new stake in shares of NeoGenomics in the 3rd quarter valued at $312,000. Institutional investors own 98.50% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on the stock. Jefferies Financial Group assumed coverage on shares of NeoGenomics in a research report on Tuesday, December 10th. They set a “buy” rating and a $22.00 target price for the company. Bank of America raised their price objective on shares of NeoGenomics from $18.00 to $19.00 and gave the stock a “neutral” rating in a report on Friday, December 13th. Benchmark reiterated a “buy” rating and issued a $18.00 target price on shares of NeoGenomics in a research note on Tuesday, September 24th. Finally, Needham & Company LLC restated a “buy” rating and set a $19.00 price target on shares of NeoGenomics in a research report on Wednesday, November 6th. One equities research analyst has rated the stock with a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $20.30.

Insider Buying and Selling at NeoGenomics

In related news, General Counsel Alicia C. Olivo sold 5,175 shares of the company’s stock in a transaction dated Friday, November 15th. The stock was sold at an average price of $15.36, for a total value of $79,488.00. Following the completion of the sale, the general counsel now owns 37,129 shares in the company, valued at approximately $570,301.44. This represents a 12.23 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Corporate insiders own 1.30% of the company’s stock.

NeoGenomics Stock Up 0.1 %

NASDAQ:NEO opened at $16.41 on Friday. The company has a market cap of $2.11 billion, a price-to-earnings ratio of -26.90 and a beta of 1.24. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.91 and a current ratio of 1.99. The stock’s fifty day moving average price is $15.74 and its two-hundred day moving average price is $15.25. NeoGenomics, Inc. has a 52-week low of $12.77 and a 52-week high of $21.22.

NeoGenomics (NASDAQ:NEO) last issued its quarterly earnings results on Tuesday, November 5th. The medical research company reported $0.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.04. The business had revenue of $167.80 million for the quarter, compared to analyst estimates of $167.00 million. NeoGenomics had a negative return on equity of 2.11% and a negative net margin of 12.07%. The firm’s revenue for the quarter was up 10.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.06) earnings per share. On average, analysts anticipate that NeoGenomics, Inc. will post -0.16 EPS for the current year.

About NeoGenomics

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.